4 results on '"Petit, Antoine"'
Search Results
2. Imported leishmaniasis in travelers: a 7-year retrospective from a Parisian hospital in France.
- Author
-
Aissaoui N, Hamane S, Gits-Muselli M, Petit A, Benderdouche M, Denis B, Alanio A, Dellière S, Bagot M, and Bretagne S
- Subjects
- France epidemiology, Hospitals, Humans, Retrospective Studies, Leishmania infantum genetics, Leishmaniasis, Leishmaniasis, Cutaneous diagnosis, Leishmaniasis, Cutaneous epidemiology, Leishmaniasis, Visceral diagnosis, Leishmaniasis, Visceral epidemiology
- Abstract
Background: Leishmaniases are regularly seen in non-endemic areas due to the increase of international travels. They include cutaneous leishmaniases (CL) and mucocutaneous (MC) caused by different Leishmania species, and visceral leishmaniases (VL) which present with non-specific symptoms., Methods: We reviewed all consecutive leishmaniasis cases seen between September 2012 and May 2020. The diagnostic strategy included microscopy after May-Grünwald-Giemsa staining, a diagnostic quantitative PCR (qPCR) assay, and species identification based on sequencing of the cytochrome b gene., Results: Eighty-nine patients had a definitive leishmaniasis diagnosis. Nine patients had VL with Leishmania infantum. Eighty patients had CL. Twelve patients acquired CL after trips in Latin America (7 Leishmania guyanensis, 2 Leishmania braziliensis, 2 Leishmania mexicana, and 1 Leishmania panamensis). Species could be identified in 63 of the 68 CLs mainly after travel in North Africa (59%) with Leishmania major (65%), Leishmania tropica/killicki (24%), and L. infantum (11%), or in West Sub-Saharan Africa (32%), all due to L. major. The median day between appearance of the lesions and diagnosis was 90 [range 60-127]., Conclusions: Our diagnostic strategy allows both positive diagnoses and species identifications. Travelers in West Sub-Saharan Africa and North Africa should be better aware of the risk of contracting leishmananiasis., (© 2021. The Author(s).)
- Published
- 2021
- Full Text
- View/download PDF
3. Relationship between cutaneous polyarteritis nodosa (cPAN) and macular lymphocytic arteritis (MLA): Blinded histologic assessment of 35 cPAN cases.
- Author
-
Buffiere-Morgado A, Battistella M, Vignon-Pennamen MD, de Masson A, Rybojad M, Petit A, Cordoliani F, Begon E, Flageul B, Mahr A, Bagot M, and Bouaziz JD
- Subjects
- Adult, Age Distribution, Aged, Aged, 80 and over, Arteritis diagnosis, Arteritis epidemiology, Biopsy, Needle, Cohort Studies, Databases, Factual, Diagnosis, Differential, Female, France, Humans, Immunohistochemistry, Incidence, Kaplan-Meier Estimate, Lymphocytes metabolism, Male, Middle Aged, Polyarteritis Nodosa diagnosis, Polyarteritis Nodosa epidemiology, Retrospective Studies, Severity of Illness Index, Sex Distribution, Single-Blind Method, Statistics, Nonparametric, Young Adult, Arteritis pathology, Lymphocytes pathology, Polyarteritis Nodosa pathology
- Abstract
Background: Cutaneous polyarteritis nodosa (cPAN) is a skin medium vessel neutrophilic arteritis with livedo, nodules, and ulcerations. Macular lymphocytic arteritis (MLA) is a small arteritis with erythematous or pigmented macules and typical histologic features (a lymphocytic infiltrate, concentric fibrin ring, no disruption of the internal elastic lamina)., Objective: We sought to assess the frequency of clinical and histologic features of MLA in patients with cPAN., Methods: This was a monocentric retrospective analysis of patients given the diagnosis of cPAN with blinded assessment of skin biopsy specimens., Results: All 35 patients included had an infiltrated livedo, nodules, or both. Ulceration was rare. Erythematous or pigmented lesions were present in 54% of patients. Predominantly lymphocytic arteritis, a paucity of neutrophils, concentric fibrin ring, and absence of internal lamina elastic disruption were present in 60%, 20%, 18%, and 23% of patients, respectively. Median follow-up was 11 years. None of the patients had systemic involvement, and 57% had a complete remission. The incidence of complete remission was not different between patients having a predominant lymphocyte infiltrate or few neutrophils., Limitations: This was a retrospective, monocentric study without a control group of patients with MLA., Conclusions: Our data do not favor the classification of cPAN and MLA as distinct entities., (Copyright © 2015 American Academy of Dermatology, Inc. Published by Elsevier Inc. All rights reserved.)
- Published
- 2015
- Full Text
- View/download PDF
4. The clinical spectrum and therapeutic management of hypocomplementemic urticarial vasculitis: data from a French nationwide study of fifty-seven patients.
- Author
-
Jachiet M, Flageul B, Deroux A, Le Quellec A, Maurier F, Cordoliani F, Godmer P, Abasq C, Astudillo L, Belenotti P, Bessis D, Bigot A, Doutre MS, Ebbo M, Guichard I, Hachulla E, Héron E, Jeudy G, Jourde-Chiche N, Jullien D, Lavigne C, Machet L, Macher MA, Martel C, Melboucy-Belkhir S, Morice C, Petit A, Simorre B, Zenone T, Bouillet L, Bagot M, Frémeaux-Bacchi V, Guillevin L, Mouthon L, Dupin N, Aractingi S, and Terrier B
- Subjects
- Adolescent, Adult, Aged, Aged, 80 and over, Colchicine pharmacology, Colchicine therapeutic use, Comorbidity, Female, France epidemiology, Humans, Hydroxychloroquine pharmacology, Hydroxychloroquine therapeutic use, Immunologic Deficiency Syndromes epidemiology, Immunologic Deficiency Syndromes pathology, Immunosuppressive Agents pharmacology, Immunosuppressive Agents therapeutic use, Male, Middle Aged, Retrospective Studies, Skin drug effects, Treatment Outcome, Urticaria epidemiology, Urticaria pathology, Vasculitis epidemiology, Vasculitis pathology, Young Adult, Complement C1q deficiency, Immunologic Deficiency Syndromes drug therapy, Skin pathology, Urticaria drug therapy, Vasculitis drug therapy
- Abstract
Objective: Hypocomplementemic urticarial vasculitis (HUV) is an uncommon vasculitis of unknown etiology that is rarely described in the literature. We undertook this study to analyze the clinical spectrum and the therapeutic management of patients with HUV., Methods: We conducted a French nationwide retrospective study that included 57 patients with chronic urticaria, histologic leukocytoclastic vasculitis, and hypocomplementemia. We assessed clinical and laboratory data and evaluated the patients' cutaneous and immunologic responses to therapy. We evaluated treatment efficacy by measuring the time to treatment failure., Results: Urticarial lesions were typically more pruritic than painful and were associated with angioedema in 51% of patients, purpura in 35%, and livedo reticularis in 14%. Extracutaneous manifestations included constitutional symptoms (in 56% of patients) as well as musculoskeletal involvement (in 82%), ocular involvement (in 56%), pulmonary involvement (in 19%), gastrointestinal involvement (in 18%), and kidney involvement (in 14%). Patients with HUV typically presented with low C1q levels and normal C1 inhibitor levels, in association with anti-C1q antibodies in 55% of patients. Hydroxychloroquine or colchicine seemed to be as effective as corticosteroids as first-line therapy. In patients with relapsing and/or refractory disease, rates of cutaneous and immunologic response to therapy seemed to be higher with conventional immunosuppressive agents, in particular, azathioprine, mycophenolate mofetil, or cyclophosphamide, while a rituximab-based regimen tended to have higher efficacy. Finally, a cutaneous response to therapy was strongly associated with an immunologic response to therapy., Conclusion: HUV represents an uncommon systemic and relapsing vasculitis with various manifestations, mainly, musculoskeletal and ocular involvement associated with anti-C1q antibodies, which were found in approximately half of the patients. The best strategy for treating HUV has yet to be defined., (Copyright © 2015 by the American College of Rheumatology.)
- Published
- 2015
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.